Francis Wheeler

Cooley advised VISEN Pharmaceuticals, a late-stage, near-commercialization biopharmaceutical company focused on providing treatments for select endocrine diseases in Greater China (including Hong Kong, Macau and Taiwan), on its HK$783 million (approximately US$101 million) initial public offering (IPO) on the Stock Exchange of Hong Kong, subject to the exercise of a 15% overallotment option.

Cooley advised Nuvation Bio (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, on its nondilutive financings of up to $250 million with Sagard Healthcare Partners.

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Cooley advised Tvardi Therapeutics, a privately held, clinical-stage biopharmaceutical company focused on the development of novel, oral, small-molecule therapies targeting STAT3 to treat fibrosis-driven diseases, on its definitive merger agreement to combine in an all-stock transaction with Cara Therapeutics (Nasdaq: CARA), a development-stage biopharmaceutical company that has been leading a new treatment paradigm to improve the lives of patients suffering from pruritus.

Cooley advised Vance Street Capital, a Los Angeles-based middle-market private equity firm that invests in highly engineered solutions businesses across the industrial technology, medical, life sciences, aerospace and defense sectors, on its acquisition of System Seals, a designer and manufacturer of custom fluid seals for various industrial applications.